… similar cardiovascular and cerebrovascular safety of LABA … with inhaled long-acting
bronchodilator combination therapy. … of cardiovascular and cerebrovascular mortality and …

… In all, the long-acting bronchodilators recommended as first-… comparable cardiovascular and
cerebrovascular safety profiles. In … a safety advantage to tiotropium as the initial long-acting …

… cardiovascular and cerebrovascular safety of adding a second long-acting bronchodilator in
… , we assessed the comparative safety of adding a second long-acting bronchodilator (either …

… the cardiovascular safety of inhaled long-acting bronchodilators. … Cardio- and cerebrovascular
safety, including MACE, AF or … cardio- and cerebrovascular events across three groups. …

Combining a long-acting β 2 -agonist (LABA) with a long-acting anti-muscarinic agent (LAMA)
provides synergistic benefit on airway smooth muscle relaxation, which may have major …

… In conclusion, the CCV safety profile of indacaterol compares favourably with existing
long-acting bronchodilator treatments. The acceptable CCV safety profile of indacaterol in a …

… safety end points for the GLY/IND FDC, which had a safety … risk of cardiovascular and
cerebrovascular SAEs, death, and … a second long-acting bronchodilator agent did not increase …

… acting bronchodilator; however, the cause of death was not specific to cardiovascular or
cerebrovascular … Therefore, the aim of this study is to examine the real-world CCV safety of LABA/…

… We examine what is already known regarding the CV and cerebrovascular safety of
LAMA/LABA … safety of inhaled long-acting bronchodilators in individuals with chronic obstructive …

… safety of tiotropium have not confirmed these safety concerns. Because of the relatively limited
amount of safety data for the newer long-acting … accumulate additional safety information …